Your essential biotech, medtech, and pharma recap — no noise, just what matters.

The Reuters M&A analysis published Thursday puts the 2026 deal wave in historical context. Q1 deal value hit $84B, nearly double the $44.4B in Q1 2025, and the strongest start to a year since 2019. If the current pace holds through Q4, total 2026 biopharma M&A could exceed $250B. That would be the second-highest total in history, behind only 2019 (which included BMS/Celgene). The drivers are structural, not cyclical: the patent cliff is creating $320B in revenue exposure by 2030 (per industry estimates), cash reserves are deep, biotech valuations remain below 2021 highs, and a wave of positive Phase 3 readouts is creating acquisition targets with de-risked assets. Lilly alone has deployed approximately $20B across six deals. Gilead committed $15B across three. Merck, AbbVie, and Novartis have all been active. Teva's $900M Emalex acquisition is notable because it shows mid-cap pharma is now joining the spree, not just the mega-caps. Teva's CEO Richard Francis called it "our Pivot to Growth strategy in action." The Foundayo launch narrative continues to develop: Lilly reported 20,000+ patients have started the drug, but the Week 2 TRx of 3,707 remains below analyst expectations of approximately 8,000. Novo's oral Wegovy hit 18,410 in its second full week. The competitive gap is real. Whether it closes depends on the trajectory over the next 4 to 8 weeks. 👉 Read Full Analysis

Teva Acquires Emalex for Up to $900M in Its Biggest Deal in a Decade TEVA

What Happened: Teva announced a definitive agreement on April 29 to acquire Emalex Biosciences for $700M upfront plus up to $200M in commercial milestones and royalties on global ecopipam net sales. Teva will fund the upfront from cash on hand. Close expected by Q3 2026.

The Asset: Ecopipam is a first-in-class selective dopamine D1 receptor antagonist being developed for pediatric Tourette syndrome, a condition with significant unmet need. Ecopipam has FDA Orphan Drug and Fast Track designations. Positive Phase 3 data demonstrated statistically significant improvement on the primary efficacy endpoint. NDA submission is anticipated in H2 2026. No approved treatments currently exist that selectively target the D1 receptor in Tourette syndrome.

Executive Impact: CEO Richard Francis called it "our Pivot to Growth strategy in action." Jefferies analyst Dennis Ding described the deal as "interesting" and said it "makes sense" given the synergies between ecopipam and Teva's existing neurology portfolio (including Austedo for tardive dyskinesia and Huntington's chorea). BioPharma Dive called it Teva's largest deal in a decade. The acquisition is part of Teva's broader transformation from a generics-focused company to one with a growing innovative pipeline.

Purdue Pharma Ceases Operations; Knoa Pharma Emerges

Purdue Pharma permanently ceased operations on May 1, 2026, following the conclusion of its Chapter 11 bankruptcy proceedings. Knoa Pharma began operations as an independent successor company focused on ensuring safe access to critical medicines and supporting communities affected by the opioid crisis. The closure ends the corporate existence of one of the most controversial pharmaceutical companies in American history.

Reuters reported on May 1 that biopharma dealmaking is on pace for its biggest year since 2019:

👉 Read Full Analysis

Reuters' analysis using Dealogic data puts the 2026 M&A surge in perspective. Q1 deal value of $84B is nearly double Q1 2025 ($44.4B) and represents the strongest start to a year since 2019. If the current pace holds, total 2026 deal value could exceed $250B.

For context, 2019 holds the all-time record (Dealogic), driven by the BMS/Celgene mega-merger. Jefferies estimated $111B in total 2025 M&A. A $250B year in 2026 would represent a step-change, not just a recovery.

Three analysts, four investors, and a banker told Reuters the surge is "broader and more durable than just a rebound to pre-COVID years." The structural drivers are clear: the patent cliff creates urgency (Keytruda 2028, Humira ongoing, Eliquis ongoing), cash reserves are deep (BMO estimated $18.6B for Amgen, $33.6B for AbbVie, $53B for Novartis earlier this year), and a wave of positive Phase 3 readouts has created a historically deep pool of de-risked acquisition targets.

The pace has not slowed entering Q2. April alone saw Lilly/Kelonia ($7B), Lilly/CrossBridge ($300M), Lilly/Ajax ($2.3B), Chiesi/KalVista ($1.9B), Teva/Emalex ($900M), UCB/Neurona ($1.15B), and multiple licensing deals (AbbVie/Kestrel, Lilly/Profluent). May is setting up to be equally active, with ASCO data drops likely to create new acquisition targets.

The gap between 3,707 TRx and the 20,000+ patients Ricks cited suggests a significant portion of Foundayo prescriptions are flowing through channels IQVIA does not fully capture (LillyDirect, certain telehealth platforms). Lilly noted 12+ telehealth firms account for ~35% of launch volume.

For comparison, Novo's oral Wegovy: Week 1 was 3,071, Week 2 was 18,410. The 5x gap in Week 2 is the number that spooked investors and led to the LLY stock decline prior to the Q1 earnings beat.

Revised 2026 Foundayo revenue estimates range from $1.3B to $1.7B, down from initial expectations of $4B to $5B. At 3,707 TRx/week, Foundayo is tracking toward ~130,000 total prescriptions by year-end. The low end of estimates ($1.3B) requires ~300,000. Foundayo needs to roughly triple its weekly run rate. Achievable but not guaranteed.

Teva's acquisition of Emalex is part of a broader strategic pivot from generics to innovation. The company has been building a growing innovative portfolio around Austedo (tardive dyskinesia, Huntington's chorea), Ajovy (migraine), and Uzedy (schizophrenia). Ecopipam adds a first-in-class neuroscience asset with NDA-ready Phase 3 data and a clear commercial opportunity.

Tourette syndrome affects approximately 1 in 160 children aged 5 to 17 in the U.S. There are currently no FDA-approved D1-selective treatments. Existing options (antipsychotics) carry significant side-effect burdens. Ecopipam's D1 selectivity is the key differentiator: it avoids the D2 receptor blockade that causes many of the sedation and metabolic side effects associated with current treatments.

Jefferies called it Teva's largest deal in a decade and said the synergies with Teva's neurology commercial infrastructure "make sense." The NDA filing in H2 2026 positions ecopipam for potential approval in 2027, giving Teva a new growth driver as it navigates the generics pricing pressures that have weighed on the company for years.

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →